Fig. 1From: Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trialStudy design flowchart. EF ejection fraction, GLS global longitudinal strain, HbA 1c glycated haemoglobin, LA left atrium, TBW total body water, VO 2 max O2 consuption at peak of stressBack to article page